Filing Flows › Immunocore Holdings (IMCR) › Q2 2026 › vs Q2 2025
Immunocore Holdings (IMCR) Q2 2026 vs Q2 2025 (year over year)
Immunocore Holdings's revenue rose $18.0M (+18%) from $98.0M in Q2 2025 to $116M in Q2 2026.
Immunocore Holdings, Q2 2026: revenue $116M (+18% year over year), operating margin -2.6%, net loss $808K, operating cash flow $15.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 13.1% | 26.1% | -13.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $116M | $98.0M | $18.0M | +18% |
| Other income, net | $2.5M | $5.2M | −$2.7M | -52% |
| Net loss | $808K | $10.3M | −$9.5M | -92% |
| Costs & expenses | $119M | $113M | $5.8M | +5% |
| Operating costs | $119M | $113M | $6.1M | +5% |
| Income tax | $294K | $606K | −$312K | -51% |
| Cost of revenue | $1.1M | $1.0M | $48K | +5% |
| Research & development | $73.9M | $69.0M | $4.9M | +7% |
| SG&A | $43.9M | $42.8M | $1.1M | +3% |
| Operating cash sources | $16.7M | $36.3M | −$19.5M | -54% |
| Depreciation | $1.0M | $780K | $246K | +32% |
| Share-based compensation | $9.4M | $10.0M | −$629K | -6% |
| Working capital & other | $6.3M | $25.5M | −$19.1M | -75% |
| Net loss absorbed | $808K | $10.3M | −$9.5M | -92% |
| Operating cash flow | $15.9M | $26.0M | −$10.0M | -39% |
| Free cash flow (OCF − capex) | $15.1M | $25.6M | −$10.4M | -41% |
| Capital expenditures | $786K | $414K | $372K | +90% |
Questions
How much did Immunocore Holdings's revenue grow year over year in Q2 2026?
Immunocore Holdings's revenue rose $18.0M (+18%) from $98.0M in Q2 2025 to $116M in Q2 2026.